Effects of tofogliflozin treatment on suppression of nocturia and promotion of urinary sodium excretion.

Effects of tofogliflozin treatment on suppression of nocturia and promotion of urinary sodium excretion. - Effects of tofogliflozin treatment on suppression of nocturia and promotion of urinary sodium excretion.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048030

Enrollment

Registered

2022-06-11

Start date

2022-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Switching from other SGLT2 inhibitors to tofogliflozin, and taking 20 mg of tofogliflozin once a day for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who are taking any SGLT2 inhibitors other than tofogliflozin

Exclusion criteria

Exclusion criteria: 1) Type 2 diabetic patients who have an allergy against SGLT2 inhibitors 2) Type 2 diabetic patients who are pregnant

Design outcomes

Primary

Measure	Time frame
Changes in nocturia (number of nighttime urination) and urinary sodium excretion at baseline and 12 weeks after tofogliflozin treatment	—

Secondary

Measure	Time frame
Changes in body weight, BMI, blood pressure, fasting plasma glucose, HbA1c, serum creatinine, eGFR, urinary albumin, LDL-cholesterol, HDL-cholesterol, triglyceride, AST, ALT, gamma-GTP at baseline and 12 weeks after tofogliflozin treatment	—

Countries

Japan

Contacts

Public ContactHiroki Fujita

Akita University Graduate School of Medicine Department of Metabolism and Endocrinology

hirofuji@gipc.akita-u.ac.jp018-884-6769

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026